Our study evidenced an important clue that pioglitazone attenuated hepatic steatosis by amplifying cytosolic lipolysis, β-oxidation, and lipophagy, which were differentially mediated by both PPARα and PPARγ. The gene discussed is PPARA; the disease is fatty liver disease.